The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Utility of tumor marker levels in predicting survival of patients with appendiceal adenocarcinoma.
 
Abdelrahman M.G. Yousef
No Relationships to Disclose
 
Aditya More
No Relationships to Disclose
 
Mohammad A. Zeineddine
No Relationships to Disclose
 
Saikat Chowdhury
Patents, Royalties, Other Intellectual Property - Sarkar, R.R., Chowdhury, S. (2021) Method to predict pathological grade and to identify drug targets against glioma tumor. US17/154,379 filed on July 29, 2021. Patent Pending; Sarkar, R.R., Ganguli, P., Chowdhury, S. (2020) Identification of minimal combinations of molecules that act as probable immunostimulators against Leishmaniasis. US15/776,008 filed on January 16, 2020. Patent Pending
 
Yue Gu
Employment - MD Anderson Cancer Center
Research Funding - MD Anderson Cancer Center
 
Julia Dansby
No Relationships to Disclose
 
Zahra Alavi Naini
No Relationships to Disclose
 
Abhineet Uppal
No Relationships to Disclose
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Eisai; Seagen
Speakers' Bureau - Bayer
Research Funding - Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Guardant Health (Inst); HiberCell (Inst); Merck Serono (Inst); Roche/Genentech (Inst)
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Eisai; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Keith F. Fournier
No Relationships to Disclose
 
John Paul Y.C. Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax
Consulting or Advisory Role - Engine Biosciences
Research Funding - Celsius Therapeutics; Celsius Therapeutics